AIM ImmunoTech reported Q3 2024 revenue of $35.0K, missed analyst consensus of $100.0K by $65.0K. Diluted EPS came in at $-6.00, beat the $-10.00 consensus by $4.00.
Trailing eight quarters through Q3 2024
Common questions about AIM ImmunoTech's Q3 2024 earnings report.
AIM ImmunoTech (AIM) reported Q3 2024 earnings on November 14, 2024 before market open.
AIM ImmunoTech reported revenue of $35.0K and diluted EPS of $-6.00 for Q3 2024.
Revenue missed the consensus estimate of $100.0K by $65.0K. EPS beat the consensus estimate of $-10.00 by $4.00.
You can read the 10-Q periodic report (0001493152-24-045971) directly on SEC EDGAR. The filing index links above go to sec.gov.